SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...

SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™  TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....